William Blair & Company
TGTX icon

William Blair & Company’s TG Therapeutics TGTX Stock Holding History

William Blair & Company’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,000
Closed -$190K – 2002
2021
Q4 		$190K Hold
10,000
– – ﹤0.01% 1592
2021
Q3 		$333K Sell
10,000
-1,250
-11% -$38.7K ﹤0.01% 1307
2021
Q2 		$436K Buy
11,250
+1,000
+10% +$39.3K ﹤0.01% 1199
2021
Q1 		$494K Hold
10,250
– – ﹤0.01% 1125
2020
Q4 		$533K Sell
10,250
-15,000
-59% -$507K ﹤0.01% 1064
2020
Q3 		$676K Hold
25,250
– – ﹤0.01% 886
2020
Q2 		$492K Buy
25,250
+15,250
+153% +$246K ﹤0.01% 945
2020
Q1 		$98K Buy
+10,000
New +$126K ﹤0.01% 1312

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

William Blair & Company's TGTX Position: Q1 2022 in Review

William Blair & Company sold out of TG Therapeutics (TGTX) in Q1 2022, closing a stake of 10,000 shares — an estimated $190K sold.

William Blair & Company first reported a position in TGTX in Q1 2020 and held it in 8 quarters. The position peaked at $676K in Q3 2020. 181 funds tracked by Wall St. Rank hold TGTX as of Q1 2022.

  • William Blair & Company reported no remaining TG Therapeutics position as of Q1 2022 after selling out during the quarter.
  • William Blair & Company sold 10,000 TG Therapeutics shares in Q1 2022, an estimated $190K.
  • William Blair & Company first reported a position in TG Therapeutics in Q1 2020 and held it in 8 quarters.
  • William Blair & Company's TG Therapeutics position peaked at $676K in Q3 2020.
  • 181 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2022.

Based on William Blair & Company's 13F filing for Q1 2022, filed 13 May 2022.